123.

Rubin M. Design of chelates for therapeutic objectives. Fed. Proceed. 20, Suppl. 10. 1961; 2:149-157 (Sept.) (2327) The author recounts the start of his work with EDTA and related compounds by undertaking toxicologic tests in 1948 at the suggestion of the Food and Drug Administration, toward the potential use of it in food as rancidity and discoloration inhibitor. Feeding experiments in animals were followed by parenteral administration, which revealed the binding capacity with Ca, and subsequently with metals. This led to the consideration of possible medical use of the nontoxic form of CaEDTA. Although it was not very effective in experimental acute Pb poisoning (because of non-identity of animal studies with the clinical course in humans) a clinical trial in a severe case of Pb poisoning in a child was undertaken. The author remarks that this application of CaEDTA in Pb poisoning provides an example of the recognition of physical and chemical properties of a compound which led to its testing and application in a preselected area of therapy.

Gordon Research Institute / Reference Material

Gordon Research Institute    Dr. Garry F. Gordon MD DO MD(H)
600 N Beeline Hwy, Suite B, Payson, AZ 85541
Phone: 928-472-4263    Fax: 928-474-3819
Email Dr.Gordon